Johnson & JohnsonJNJ

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · jnj.com

Johnson & Johnson is a global healthcare company headquartered in New Brunswick, New Jersey, focused on pharmaceutical products and medical devices following the 2023 spin-off of its consumer health division as Kenvue. The company develops, manufactures, and markets innovative medicines and medical technologies across oncology, immunology, neuroscience, cardiovascular, and infectious disease therapeutic areas. Johnson & Johnson is one of the world's largest and most valuable healthcare companies.

Key ratios

Operating cash flow growth

-7.7%TTM

2025 1.1%2024 6.5%2023 7.5%

EPS growth

-3.9%TTM

2025 90.5%2024 11.4%2023 -15.3%

FCF / Sales

18.5%TTM

2025 20.9%2024 22.3%2023 21.6%

Net margin

21.8%TTM

2025 28.5%2024 15.8%2023 41.3%

ROA

8.4%TTM

2025 8.7%2024 8.1%2023 8.3%

ROE

26.4%TTM

2025 35.0%2024 20.1%2023 18.3%

Revenue growth

7.9%TTM

2025 6.1%2024 4.3%2023 6.5%

Recent news

European Commission approves Johnson & Johnson's TECVAYLI® (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma 2026-08-21 · GlobeNewswire Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida 2026-06-15 · Johnson & Johnson Investor Relations J&J multiple myeloma drug gains edge in earlier stage disease 2026-06-15 · BioPharma Dive

Track JNJ in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer